Fresenius Kabi AG
Fresenius Kabi AG is a German healthcare subsidiary of Fresenius SE & Co. KGaA specializing in injectable pharmaceuticals, clinical nutrition, medical devices, and biosimilars. It serves hospitals, blood centers, and chronically ill patients across 40+ countries, reaching approximately 450 million patients annually.
- Company typePrivate
- Founded1999
- HeadquartersBad Homburg, Germany
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Fresenius Kabi AG does
Fresenius Kabi AG is a German healthcare company headquartered in Bad Homburg and operating as a wholly-owned subsidiary of publicly listed Fresenius SE & Co. KGaA. The company specializes in lifesaving medicines and technologies organized across four business divisions: Pharma (injectable IV drugs including anesthetics, analgesics, anti-infectives, oncology, and critical care medications), Nutrition (parenteral IV nutrition, enteral tube feeds, and oral nutritional supplements under the Fresubin brand), MedTech (infusion pumps such as Agilia Connect with Vigilant software, apheresis and blood collection systems, anesthesia monitoring, and cell/gene therapy manufacturing technologies including the Cue and Lovo systems), and Biopharma (biosimilars such as the denosumab products Conexxence and Bomyntra).
The company generates revenue primarily through direct hospital and healthcare system sales via dedicated field sales representatives covering each division, supplemented by pharmacy and distributor networks, government tenders, and homecare service organizations (FresuCare). Pricing is negotiated through hospital purchasing groups, tenders, and government procurement rather than publicly disclosed. The company serves hospitals, blood centers, chronic care patients, homecare patients, and patients requiring biologic therapies across more than 40 countries with manufacturing facilities spanning Argentina, Brazil, China, India, Mexico, South Africa, Tunisia, the UAE, and the USA, touching approximately 450 million patients annually.
Recent strategic activity centers on the Vision 2026 growth plan, with major moves including the €495 million acquisition of majority stake in mAbxience (2022) for biosimilars, the Ivenix acquisition (2022) for infusion technology, FDA interchangeable biosimilar designation for denosumab (2025), and partnerships with Phlow Corp. (U.S. domestic Epinephrine manufacturing), TQ Therapeutics (CAR-T cell therapy), and Cellular Origins (cell therapy automation). The PULSE transformation program with Capgemini and Salesforce targets commercial process unification across all four divisions by 2029.
Fresenius Kabi AG firmographics
Firmographics- Name
- Fresenius Kabi AG
- Legal name
- Fresenius Kabi AG
- Website
- https://fresenius-kabi.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Fresenius Kabi AG is a German healthcare subsidiary of Fresenius SE & Co. KGaA specializing in injectable pharmaceuticals, clinical nutrition, medical devices, and biosimilars. It serves hospitals, blood centers, and chronically ill patients across 40+ countries, reaching approximately 450 million patients annually.
- Ownership category
- akta.pro rank
Fresenius Kabi AG industry classification
Industry- Product category
- Hospital Pharmaceuticals and Medical Devices
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Generic Hospital & Institutional Products (HLAIABAL)
Keywords
Where Fresenius Kabi AG is headquartered
LocationHeadquarters
- HQ city
- Bad Homburg
- HQ country
- Germany
- HQ region
- Europe
Offices44 records
Markets served
Fresenius Kabi AG business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceuticals (IV Drugs & Infusion Therapy): Fresenius Kabi offers injectable drugs including anesthetics, analgesics, anti-infectives, oncology drugs, and critical care medications. Revenue generated through hospital and healthcare facility sales globally.
- Medical Nutrition: Specialized clinical nutrition products including parenteral nutrition (IV), enteral nutrition (tube feeds), and oral nutritional supplements for patients unable to meet energy and protein needs through regular food.
- MedTech (Medical Devices): Advanced medical technologies including infusion pumps, apheresis devices, blood collection and processing equipment, cell therapy instruments, and monitoring systems for transfusion and infusion therapy.
- Biopharma (Biosimilars): Affordable, high-quality biopharmaceuticals including biosimilars for autoimmune diseases and cancer. Products include denosumab biosimilars Conexxence and Bomyntra for osteoporosis and bone metastases.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Monthly | Fresubin Oral Nutritional Supplements - US Market |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Fresenius Kabi AG product offering
Product offeringCore offering
Fresenius Kabi AG manufactures and sells lifesaving medicines and technologies across four divisions: Pharma (IV generic drugs and infusion therapy for anesthesia, oncology, anti-infectives, and critical care), Medical Nutrition (parenteral and enteral clinical nutrition products), MedTech (infusion pumps, apheresis and blood collection/processing systems, anesthesia monitors, and cell/gene therapy manufacturing platforms), and Biopharma (biosimilars for autoimmune diseases and cancer). The company sells primarily to hospitals, healthcare systems, blood centers, and homecare providers in more than 40 countries.
Product overview
Fresenius Kabi AG operates as a global healthcare company with four core business divisions: Pharma, Biopharma, Nutrition, and MedTech. The Pharma division offers injectable IV drugs including anesthetics, oncology treatments, anti-infectives, and critical care medications, along with generic equivalents such as Dalbavancin, Pralatrexate, Gadobutrol, Plerixafor, Rocuronium Bromide, and Epinephrine. The Biopharma division provides biosimilars including Conexxence® and Bomyntra® (denosumab products) for oncology and osteoporosis. The Nutrition division encompasses clinical nutrition products including Fresubin oral nutritional supplements, Fresubin and Freka tube feeds, parenteral nutrition (amino acids, lipid emulsions, multi-chamber bags), and keto analogues. The MedTech division supplies infusion systems (Agilia Connect pumps, Vigilant Software Suite, Volumat Lines), blood collection and processing systems (apheresis, autotransfusion, blood donation systems), anesthesia monitoring (Conox), and cell/gene therapy manufacturing technologies (Cue system, Lovo system). The company maintains operations across over 60 countries with manufacturing facilities worldwide.
Differentiator
Problem solved
Functional benefit
Brands
- Fresubin: Oral nutritional supplements and tube feeds for patients unable to meet energy and protein needs through regular food.
- FresuCare
- Conexxence
- Bomyntra
- Amika
- Freka
- KabiCare
- BioSpecialized
Products and services
- RFID-enabled Rocuronium Bromide Injection Neuromuscular blocking agent for anesthesia procedures with embedded RFID technology for drug traceability, authentication, and supply chain integrity in hospitals.
- Rocuronium Bromide Injection RTS (Room Temperature Stable) First room-temperature-stable neuromuscular blocking agent injection for anesthesia, eliminating cold chain storage and simplifying hospital logistics.
- Pralatrexate Injection Generic alternative for the treatment of relapsed or refractory peripheral T-cell lymphoma, expanding oncology injectable options.
- Dalbavancin for Injection Single-dose antibiotic injection for acute bacterial skin and skin structure infections, providing a long-acting lipoglycopeptide treatment option.
- Gadobutrol Injection MRI contrast agent for diagnostic imaging used in radiology departments.
- Plerixafor Injection Hematopoietic stem cell mobilizer used in oncology for stem cell collection prior to transplantation.
- Conexxence (denosumab-bnht) Biosimilar FDA-designated interchangeable biosimilar to Prolia (denosumab) for treating osteoporosis and bone-related conditions, providing affordable access to biologic therapy.
- Bomyntra (denosumab-bnht) Biosimilar FDA-designated interchangeable biosimilar to Xgeva (denosumab) for preventing skeletal-related events in patients with bone metastases from solid tumors.
- Agilia Connect Infusion Pump Smart infusion pump system with connectivity features for precise IV drug delivery in hospital settings, supporting infusion safety and dose-error reduction.
- Vigilant Software Suite Software platform for infusion pump fleet management, dose monitoring, drug library updates, and workflow optimization across hospital infusion operations.
- Apheresis Collection Systems Blood component collection technology for apheresis procedures at blood centers and hospitals, enabling plasma, platelet, and cellular component collection.
- Autotransfusion Devices Cell salvage systems that collect and reinfuse a patient's own blood during surgical procedures, reducing demand on donor blood supplies.
- Conox Anesthesia Monitoring System Anesthesia depth monitoring system for tracking patient vital signs and hypnotic state during surgical procedures.
- Cell and Gene Therapy Manufacturing Systems (Cue and Lovo) Automated cell therapy manufacturing platforms including the Cue Cell Processing System and Lovo system for scalable, automated production of cell and gene therapies including CAR-T.
- Fresubin Oral Nutritional Supplements Ready-to-drink oral nutritional supplements (ONS) including disease-specific formulas and powdered supplements for patients unable to meet energy and protein needs through regular food, used in hospital and home-care settings under professional supervision.
- Fresubin Tube Feeds (Enteral Nutrition) Enteral nutrition products delivered via nasogastric or gastrostomy tubes for patients requiring tube feeding in hospital or home-care settings.
- Parenteral Nutrition Macronutrients IV-administered macronutrient solutions including amino acids and lipid emulsions for patients unable to absorb nutrients enterally.
- Multi-Chamber Parenteral Nutrition Bags Pre-mixed parenteral nutrition bags combining macronutrients and micronutrients in ready-to-use formats for simplified clinical administration.
- Freka Enteral Feeding Tubes Gastrostomy and nasogastric feeding tubes for enteral nutrition administration in clinical and home-care settings.
- Amika Enteral Feeding Pump Portable enteral nutrition pump for home use, providing portable infusion delivery for patients on long-term tube feeding.
- Volumat Lines (Infusion Administration Sets) Administration sets and tubing consumables for use with infusion pumps in IV therapy delivery.
Quantifiable outcome
- Touches lives of almost 450 million people every year
- +3 more outcomes
Companies that use Fresenius Kabi AG
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
Fresenius Kabi AG technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Fresenius Kabi AG partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Phlow Corp.coreFirst-of-its-kind collaboration to onshore domestic manufacture of Epinephrine Injection in the U.S. Phlow produces the active pharmaceutical ingredient (API) while Fresenius Kabi handles formulation and finished dose production. Product expected to be available to U.S. hospitals by 2027, with partnership scalable to other essential medicines.
- Cellular OriginscoreCollaboration integrating Fresenius Kabi's Cue Cell Processing System into Cellular Origins' Constellation CGT robotic manufacturing platform. Phase one complete with studies confirming reliable execution of complex workflows. Focus now on scaling for clinical and commercial manufacturing and integration into Fresenius Kabi's wider cell therapy portfolio including Lovo system.
- TQ TherapeuticscoreStrategic development agreement granting Fresenius Kabi exclusive rights to develop, manufacture, and distribute products using TQ's cell selection technology. Integration into Fresenius Kabi's Cue system enables scalable, automated CAR-T therapy production at patient's bedside in under five hours. TQ Therapeutics previously acquired Juno Therapeutics GmbH (German subsidiary of CAR-T pioneer Juno Therapeutics, now part of Bristol Myers Squibb).
- National Infusion Collaborative (NIC)minorFresenius Kabi USA joined NIC, a major vendor-agnostic network of infusion practitioners in the United States. Participation aims to enhance infusion safety, optimize workflows, and share best practices with hospitals and health systems nationwide.
- CapgeminiminorCapgemini serves as implementation partner for Fresenius Kabi's global PULSE transformation program leveraging Salesforce Life Sciences Cloud. Initiative aims to unify commercial processes across Pharma, BioPharma, Nutrition, and MedTech business units by 2029.
- mAbxience Holding S.L.coreFresenius Kabi completed acquisition of majority stake in mAbxience Holding S.L. for approximately €495 million upfront payment plus milestone payments. The transaction strengthens Fresenius Kabi's biosimilars portfolio and provides access to innovative biologics manufacturing capabilities as part of Vision 2026 growth strategy.
- IvenixcoreFresenius Kabi announced acquisition of Ivenix, a medical technology company, to support growth strategy in medical technology. The acquisition aims to introduce advanced infusion therapy solutions, with closing expected by mid-2022.
Scale indicators6 records
Recent moves7 records
Expansion highlights7 records
Fresenius Kabi AG competitors and assessment
Company assessmentDirect peers
- Baxter International: Baxter is Fresenius Kabi's closest direct competitor, holding approximately 14% of the global IV bag market alongside Fresenius Kabi and competing in IV solutions, infusion pumps, apheresis, and clinical nutrition. Baxter's Hospital Products segment overlaps almost category-for-category with Fresenius Kabi's Pharma, MedTech, and Nutrition divisions.
- B. Braun Medical: B. Braun is a leading global competitor in IV solutions, infusion systems, clinical nutrition, and generic injectables, with a particularly strong presence in Europe. Its portfolio of OEM IV bags, infusion pumps, and clinical nutrition directly competes with Fresenius Kabi's flagship product lines across hospital channels.
- ICU Medical: ICU Medical is a focused IV therapy and infusion devices competitor, holding global IV bag share alongside Baxter and Fresenius Kabi. Its medical connector, IV solution, and infusion pump portfolios directly overlap with Fresenius Kabi's MedTech and Pharma divisions.
- Terumo Corporation: Terumo is a Japanese-headquartered direct competitor in IV solutions, blood component collection (apheresis), infusion systems, and hospital injectables. Terumo's Blood and Cell Technologies division overlaps closely with Fresenius Kabi's Fenwal blood collection franchise.
- Drägerwerk: Drägerwerk is a German medical technology competitor specializing in anesthesia monitoring, patient monitoring, and acute-care hospital equipment. Its anesthesia delivery systems overlap with Fresenius Kabi's Conox monitoring and infusion pump portfolio.
Broad incumbents
- Abbott Laboratories: Abbott competes in clinical nutrition (via its Established Pharmaceuticals and nutrition businesses) and is identified alongside Fresenius Kabi as a key player in the global clinical nutrition market. Abbott's broader portfolio also includes diagnostics and devices that touch the same hospital customers.
- Nestlé Health Science: Nestlé Health Science is a leading global competitor in clinical and medical nutrition, including oral nutritional supplements and tube feeds. It competes directly with Fresenius Kabi's Fresubin brand and is identified alongside Fresenius Kabi as a key clinical nutrition market player.
- Pfizer (Hospital / Injectables): Pfizer's Hospital portfolio (including the legacy Hospira injectable generics franchise) is a major supplier of generic sterile injectables in the U.S. and globally, competing with Fresenius Kabi's Dalbavancin, Pralatrexate, and other generic injectable launches.
- Teva Pharmaceutical Industries: Teva is a global leader in generic injectables and specialty pharmaceuticals, with a portfolio that competes with Fresenius Kabi's generic injectable launches and broader hospital injectables franchise across U.S. and European channels.
- Danone (Medical Nutrition): Danone's Medical Nutrition business (including Nutricia) competes with Fresenius Kabi in clinical nutrition for chronic disease patients. It is identified alongside Fresenius Kabi, Abbott, and Nestlé Health Science as a key player in the clinical nutrition market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Fresenius Kabi AG social profiles
Digital presenceFresenius Kabi AG compliance and trust
Trust signalCompliance3 records
Fresenius Kabi AG financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fresenius Kabi AG leadership team
Management profileNumber of profiles
Profiles7 records
Fresenius Kabi AG subsidiaries and ownership
Company hierarchySubsidiaries18 records
Fresenius Kabi AG funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fresenius Kabi AG M&A and investment
M&A and investmentM&A6 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fresenius Kabi AG
What does Fresenius Kabi AG do?
Fresenius Kabi AG manufactures and sells lifesaving medicines and technologies across four divisions: Pharma (IV generic drugs and infusion therapy for anesthesia, oncology, anti-infectives, and critical care), Medical Nutrition (parenteral and enteral clinical nutrition products), MedTech (infusion pumps, apheresis and blood collection/processing systems, anesthesia monitors, and cell/gene therapy manufacturing platforms), and Biopharma (biosimilars for autoimmune diseases and cancer). The company sells primarily to hospitals, healthcare systems, blood centers, and homecare providers in more than 40 countries.
Is Fresenius Kabi AG a public or private company?
Fresenius Kabi AG is a private company. It is classified as corporate owned and is currently operating.
When was Fresenius Kabi AG founded?
Fresenius Kabi AG was founded in 1999. It employs 1,001 to 5,000 people.
Where is Fresenius Kabi AG based?
Fresenius Kabi AG is headquartered in Bad Homburg, Germany, in the Europe region.
How does Fresenius Kabi AG make money?
Four revenue lines are on record. Pharmaceuticals (IV Drugs & Infusion Therapy) is the primary driver. The others are medical Nutrition, medTech (Medical Devices) and biopharma (Biosimilars).
Who are Fresenius Kabi AG's main competitors?
Direct peers on record are Baxter International, B. Braun Medical, ICU Medical, Terumo Corporation and Drägerwerk. Broad incumbents are Abbott Laboratories, Nestlé Health Science, Pfizer (Hospital / Injectables), Teva Pharmaceutical Industries and Danone (Medical Nutrition).
Does Fresenius Kabi AG have an API?
No public API is recorded for Fresenius Kabi AG.
What industry is Fresenius Kabi AG in?
Fresenius Kabi AG's product category is Hospital Pharmaceuticals and Medical Devices. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.